<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192361</url>
  </required_header>
  <id_info>
    <org_study_id>D153 P500</org_study_id>
    <nct_id>NCT00192361</nct_id>
  </id_info>
  <brief_title>Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)</brief_title>
  <official_title>A Randomized, Double-Blind Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine, Trivalent, Types A &amp; B, Live Cold-Adapted (CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      To assess whether CAIV-T was transmitted from vaccinated children to their unvaccinated&#xD;
      contacts in a day care setting; and if so, to estimate the rate of transmission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study was the determination of the proportion of placebo recipients from whom any of the vaccine strains were isolated.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The endpoint for children who received CAIV-T was the first nasal swab scored positive for viral shedding in</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>which the vaccine virus phenotype (cold-adapted and temperature sensitive) or genotype (6:2 reassortant) was</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>not preserved. Genotypic and phenotypic stability were summarized as the proportion of all vaccine viruspositive</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>isolates which retained the cold-adapted phenotype, temperature-sensitive phenotype or the 6:2</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reassortant genotype of the vaccine strains.</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  who were at least 8 months and less than 36 months of age (had not reached their 3rd&#xD;
             birthday) at the time of enrollment, and in good health as determined by medical&#xD;
             history, physical examination, and clinical judgment;&#xD;
&#xD;
          -  whose parent or legal guardian had provided written informed consent after the nature&#xD;
             of the study had been explained;&#xD;
&#xD;
          -  who, along with their parent or legal guardian, were available for the duration of the&#xD;
             study (42 days post-vaccination of first study dose or 42 days post-vaccination of&#xD;
             supplemental dose of CAIV-T);&#xD;
&#xD;
          -  whose parent/legal guardian could be reached by telephone by study staff for the&#xD;
             postimmunization contacts;&#xD;
&#xD;
          -  who attended day care at least three days per week and four hours per day;&#xD;
&#xD;
          -  who was one of at least 4 children in a contact group/playroom (at least 4 children in&#xD;
             such a group were required to be randomized in the study).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  whose parents or legal guardians were perceived to be unreliable or unavailable for&#xD;
             evaluation or study visits during the study period;&#xD;
&#xD;
          -  with any serious chronic disease (e.g., with signs of cardiac or renal failure or&#xD;
             severe malnutrition), including progressive neurological disease and asthma;&#xD;
&#xD;
          -  with Down's syndrome or other known cytogenetic disorders;&#xD;
&#xD;
          -  with a known or suspected disease of the immune system or those receiving&#xD;
             immunosuppressive therapy, including systemic corticosteroids;&#xD;
&#xD;
          -  who received any blood products, including immunoglobulin, in the period from six&#xD;
             months prior to vaccination through to the conclusion of the study;&#xD;
&#xD;
          -  for whom there was intent to administer any other investigational vaccine or agent&#xD;
             from one month prior to enrollment through to the conclusion of the study;&#xD;
&#xD;
          -  with an immunosuppressed or compromised individual in the same playroom or living in&#xD;
             the same household;&#xD;
&#xD;
          -  who, at any time prior to entry into this study, received a dose of any influenza&#xD;
             vaccine (commercial or investigational);&#xD;
&#xD;
          -  with a documented history of hypersensitivity to egg or egg protein;&#xD;
&#xD;
          -  with a respiratory illness with wheezing within two weeks prior to enrollment;&#xD;
&#xD;
          -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two&#xD;
             weeks prior to enrollment or for whom use was anticipated during the study;&#xD;
&#xD;
          -  who were administered any live virus vaccine within one month prior to enrollment or&#xD;
             expected receipt of another live virus vaccine within one month of vaccination in this&#xD;
             study;&#xD;
&#xD;
          -  who were administered any inactivated vaccine within two weeks prior to enrollment or&#xD;
             expected receipt of another inactivated vaccine within three weeks of vaccination in&#xD;
             this study;&#xD;
&#xD;
          -  with any medical conditions that in the opinion of the investigator might interfere&#xD;
             with interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kauppakatu Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33101</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 23, 2006</last_update_submitted>
  <last_update_submitted_qc>October 23, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

